NeuroMetrix Inc (NURO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NeuroMetrix Inc (NURO) has a cash flow conversion efficiency ratio of -0.132x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.89 Million) by net assets ($14.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NeuroMetrix Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
NeuroMetrix Inc - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how NeuroMetrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NeuroMetrix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeuroMetrix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adelong Gold Ltd
AU:ADG
|
-0.066x |
|
HK Metals Utama Tbk PT
JK:HKMU
|
0.222x |
|
Terrain Minerals Ltd
AU:TMX
|
-0.113x |
|
Palamina Corp
V:PA
|
-1.095x |
|
Golden Pursuit Resources Ltd
V:GDP
|
0.918x |
|
Cabnet Holdings Bhd
KLSE:0191
|
0.009x |
|
Telecom Plus PLC
LSE:TEP
|
0.263x |
|
Check Cap Ltd
NASDAQ:CHEK
|
0.000x |
Annual Cash Flow Conversion Efficiency for NeuroMetrix Inc (2002–2024)
The table below shows the annual cash flow conversion efficiency of NeuroMetrix Inc from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see NeuroMetrix Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.31 Million | $-7.13 Million | -0.498x | -64.46% |
| 2023-12-31 | $20.09 Million | $-6.08 Million | -0.303x | -33.73% |
| 2022-12-31 | $23.36 Million | $-5.29 Million | -0.226x | -153.54% |
| 2021-12-31 | $23.22 Million | $-2.07 Million | -0.089x | +77.32% |
| 2020-12-31 | $5.25 Million | $-2.07 Million | -0.394x | +72.48% |
| 2019-12-31 | $2.53 Million | $-3.62 Million | -1.431x | -404.96% |
| 2018-12-31 | $6.10 Million | $2.86 Million | 0.469x | +118.61% |
| 2017-12-31 | $5.02 Million | $-12.65 Million | -2.522x | +17.05% |
| 2016-12-31 | $4.96 Million | $-15.08 Million | -3.040x | -191.53% |
| 2015-12-31 | $12.56 Million | $-13.10 Million | -1.043x | +54.00% |
| 2014-12-31 | $3.39 Million | $-7.68 Million | -2.267x | -148.83% |
| 2013-12-31 | $7.19 Million | $-6.55 Million | -0.911x | +12.62% |
| 2012-12-31 | $8.80 Million | $-9.18 Million | -1.043x | -70.56% |
| 2011-12-31 | $11.09 Million | $-6.78 Million | -0.611x | +7.21% |
| 2010-12-31 | $20.20 Million | $-13.31 Million | -0.659x | -283.34% |
| 2009-12-31 | $35.71 Million | $-6.14 Million | -0.172x | +63.29% |
| 2008-12-31 | $22.83 Million | $-10.69 Million | -0.468x | -173.81% |
| 2007-12-31 | $46.73 Million | $-7.99 Million | -0.171x | -201.69% |
| 2006-12-31 | $43.41 Million | $7.30 Million | 0.168x | +219.38% |
| 2005-12-31 | $36.25 Million | $1.91 Million | 0.053x | +167.61% |
| 2004-12-31 | $34.06 Million | $-2.65 Million | -0.078x | -191.47% |
| 2003-12-31 | $-45.50 Million | $-3.87 Million | 0.085x | -25.46% |
| 2002-12-31 | $-39.93 Million | $-4.56 Million | 0.114x | -- |
About NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endoc… Read more